Alpha Compute Corp

AlphaTON Capital Corp is a clinical-stage immuno-oncology company developing therapies that target resistance mechanisms to checkpoint inhibitors to improve anti-tumor responses. It offers a portfolio of early- to mid-stage product candidates including adenosine receptor antagonists, iNKT cell engagers, STING agonists, nanoparticle and nanolipogel delivery platforms, and related preclinical and clinical programs. Key business segments operate through subsidiaries and separate platform companies managing distinct assets (e.g., adenosine, iNKT, PORT platforms, and investee subsidiaries). Its activities are conducted through collaborations, investigator-sponsored trials, and external service providers across the U.S., U.K., Europe and other international research and clinical channels.

Summary from filing dated 2025-07-25